Protein detail
I11RA
Interleukin-11 receptor subunit alpha (IL-11 receptor subunit alpha) (IL-11R subunit alpha) (IL-11R-alpha) (IL-11RA) [Cleaved into: Soluble interleukin-11 receptor subunit alpha (sIL-11R) (sIL-11RA) (sIL11RA)]
Entry name I11RA | UniProt ID | EVMP confidence score 0.38 |
Supporting publications (n) 3 | Transmembrane count 1 | Protein classification Disease related genesFDA approved drug targetsHuman disease related genesPredicted membrane proteinsPredicted secreted proteins |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information12
Protein Names
Interleukin-11 receptor subunit alpha (IL-11 receptor subunit alpha) (IL-11R subunit alpha) (IL-11R-alpha) (IL-11RA) [Cleaved into: Soluble interleukin-11 receptor subunit alpha (sIL-11R) (sIL-11RA) (sIL11RA)]
Protein Class (5)
Disease related genesFDA approved drug targetsHuman disease related genesPredicted membrane proteinsPredicted secreted proteins
Protein Function (4)
- Disease related genes
- Predicted secreted proteins
- Human disease related genes:Congenital malformations:Other congenital malformations
- FDA approved drug targets:Biotech drugs
Transmembrane
371..391; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Description
Interleukin 11 receptor subunit alpha
Chromosome
9
Position
34652162-34661902
Supporting publications (n)
3
EVMP confidence score
0.38
Fluorescence & Localization3
Tissue SpecificbrainCell SpecificAstrocytesSingle-Nuclei Brain Specificoligodendrocyte precursor cell
Function & Pathway8
Protein Function (4)
- Disease related genes
- Predicted secreted proteins
- Human disease related genes:Congenital malformations:Other congenital malformations
- FDA approved drug targets:Biotech drugs
Cellular Component (4)
Molecular Function (4)
Biological Process (3)
KEGG (3)
Reactome (4)
Canonical Pathways
M175 Pid erbb2 erbb3 pathway
Mediation Categories (4)
Clinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence69
Ligand-Receptor Signaling (66)
66 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| ligand | ligand | Cellinker | Yes | No | Yes | Yes | No |
| ligand | ligand | OmniPath | Yes | No | Yes | Yes | No |
| receptor | receptor | talklr | No | Yes | Yes | Yes | No |
| receptor | receptor | scConnect | No | Yes | Yes | Yes | No |
| receptor | receptor | connectomeDB2020 | No | Yes | Yes | Yes | No |
| receptor | receptor | CellCall | No | Yes | Yes | Yes | No |
| receptor | receptor | iTALK | No | Yes | Yes | Yes | No |
| cytokine | receptor | iTALK | No | Yes | Yes | Yes | No |
| receptor | receptor | Almen2009 | No | Yes | Yes | Yes | No |
| receptor | receptor | CellCellInteractions | No | Yes | Yes | Yes | No |
Regulatory Interaction Network (1)
1 record.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| IL11 | P20809 | I11RA | Q14626 | Yes | Yes | No | iTALKKirouac2010SIGNORHINTSignaLink3InnateDBDIPUniProt_LRdbLit-BM-17HPMR_talklrHPMRHPRD_LRdbtalklrHPRDRamilowski2015_Baccin2019DLRP_talklrWangRamilowski2015HPMR_LRdbHPRD_talklrBaccin2019STRING_talklrCellCallGuide2PharmaCellTalkDBFantom5_LRdbconnectomeDB2020SPIKE_LCLRdb | LRdb:10504396Baccin2019:10948192LRdb:10948192SIGNOR:10948192LRdb:7670098HINT:8940087Lit-BM-17:26551460HPRD:7670098InnateDB:8940087HINT:26551460Baccin2019:10504396HPRD:10504396DIP:8940087Lit-BM-17:8940087SignaLink3:23331499Baccin2019:7670098HINT:37985757connectomeDB2020:10948192SignaLink3:12740032CellTalkDB:10948192connectomeDB2020:10504396connectomeDB2020:7670098HPMR:10948192SPIKE_LC:16189514 |
Protein Complex Composition (1)
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential UltracentrifugationSize Exclusion Chromatography | Mass spectrometry | 1 | 38716512 |
Sequence, Structure & Domains15
Sequences
Length
422
Mass
45,222
Sequence
MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWFRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSCQAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARCVVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASWTYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLDAGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHRDSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAPNL
Alternative Products
Event=Alternative splicing; Named isoforms=2; Name=HCR1; Synonyms=Membrane form, mIL11RA; IsoId=Q14626-1; Sequence=Displayed; Name=HCR2; Synonyms=Soluble form, sIL11RA; IsoId=Q14626-2; Sequence=VSP_011879
Alternative Sequence
391..422; Missing (in isoform HCR2)
3D Structural Models
Turn
86..88
Helix
212..215
Beta Strand
30..32; 35..38; 44..47; 57..61; 73..75; 78..83; 90..99; 101..109; 117..133; 139..141; 143..150; 178..183; 191..199; 204..210; 222..228; 236..241; 254..264; 269..271; 277..280; 289..297; 311..313
3D Structure
Electron microscopy (3); X-ray crystallography (2)
Domain & Motif Annotations
Compositional Bias
413..422; Basic and acidic residues
Motif
304..308; WSXWS motif
Domain (FT)
27..110; Ig-like C2-type; 112..219; Fibronectin type-III 1; 220..317; Fibronectin type-III 2
Region
335..355; Disordered; 398..422; Disordered
Protein Families (2)
- Type I cytokine receptor family
- Type 3 subfamily
Sequence Similarities
Belongs to the type I cytokine receptor family. Type 3 subfamily.
Clinical Relevance6
Disease Involvement (3)
CraniosynostosisDisease variantFDA approved drug targets
Related Diseases (2)
Biomarker
Phase 1; Approved
Drug Targets
FDA approved drug targets
Supporting Publications3
| PMID | Title | Abstract |
|---|---|---|
| 29689087 | Identification of RNA-binding proteins in exosomes capable of interacting with different types of RNA: RBP-facilitated transport of RNAs into exosomes. | To assess the involvement of these RBPs in RNA-transfer into exosomes, the gene transcripts encoding six of the proteins identified in exosomes (HSP90AB1, XPO5, hnRNPH1, hnRNPM, hnRNPA2B1, and MVP) were silenced by siRNA and subsequent effect on esRNA was assessed. |
| 32795414 | Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. | Among traditional exosome markers, CD9, HSPA8, ALIX, and HSP90AB1 represent pan-EVP markers, while ACTB, MSN, and RAP1B are novel pan-EVP markers. |
| 32841894 | Insight into the proteomic profiling of exosomes secreted by human OM-MSCs reveals a new potential therapy. | A total of 304 exosome-associated proteins were identified by LC-MS/MS, including plasminogen activator inhibitor 1 (SERPINE 1), insulin-like growth factor binding protein family members (IGFBP 4 and 5), epidermal growth factor receptor (EGFR), neurogenic locus notch homolog protein 2 (NOTCH 2), apolipoprotein E (APOE), and heat shock protein HSP90-beta (HSP90AB1). Similar to other exosomes, OM-MSC exosomes were CD63- and CD81-positive and calnexin-negative. |